The Hill reports:
A Pfizer study released Wednesday determined that the mutations in the COVID-19 variants originally found in the United Kingdom and South Africa have “small effects” on the effectiveness of the company’s vaccine developed with BioNTech.
The preliminary research, conducted by Pfizer and University of Texas Medical Branch scientists, concluded that the results showed no need for an additional vaccine for the variants.
“While these findings do not indicate the need for a new vaccine to address the emerging variants, the Companies are prepared to respond if a variant of SARS-CoV-2 demonstrates evidence of escaping immunity by the COVID-19 vaccine,” Pfizer and BioNTech said in a release.
Read the full article.
The vaccine made by Pfizer and BioNTech appears to retain its effectiveness against coronavirus mutations in worrying new variants that have emerged recently in Britain and South Africa, the firms said. https://t.co/8I28EsFksE
— IOL News (@IOL) January 28, 2021